BRAF and melanoma: These new CRISPR/Cas9 engineered isogenic models of acquired BRAF inhibitor resistance in BRAF V600E melanoma represent an important step forward for both the study of acquired BRAF inhibitor resistance and for the screening and development of novel chemotherapeutics and treatment regimens for patients with inhibitor resistant melanoma.